Breaking News


Imiquimod and intralesional interleukin-2 restores cytokine balance in patients with metastatic melanoma


A study to investigate the effects of topical imiquimod cream 5% and intralesional interleukin-2 (IL-2) in 8 patients (aged 46-80 years) with accessible melanoma metastases was conducted. An increase in the mean CD4/CD8 ratio from 2.78 to 3.54 was seen after treatment (p<0.001) and the percentage of CD25+ cells rose from 14.52% to 38.5%. There was also an increase in the interferon-gamma/IL-5 ratio in the majority of patients. This co-therapy with imiquimod and IL-2 can reverse some of the changes associated with metastatic melanoma (Green, DS. et al. Br J Dermatol 2008, 159[3]: 606-614).

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list